What is the prognostic implication of somatic IDH mutations in MDS?

Mutations in MDS - Prognostic and Therapeutic ImplicationsПодробнее

From MDS to AML: What Every Patient Needs to Know 11/28/17Подробнее

Somatic mutations in MDS as a diagnostic and prognostic toolПодробнее

The impact of IDH mutations in MDS & evaluating the role of IDH inhibitorsПодробнее

Prognostic factors and mutations in MDSПодробнее

Clinical Implications of Genetic Mutations in Myelodysplastic SyndromesПодробнее

Understanding Genetic Mutations in MDSПодробнее

Why MPN transforms to AMLПодробнее

Genetic mutations and inflammation: understanding the links and improving prognosis in MDSПодробнее

Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Подробнее

Understanding MDS Mutations and Risk ScoresПодробнее

Molecular Mutations in AML and MDS: Adverse Impact of TET2Подробнее

What is the clinical impact of DDX41 mutations in myeloid neoplasms?Подробнее

Use of Molecular Genetic Testing in MDS and MPNПодробнее

Current Understanding of a Genetic/Epigenetic Basis of MDSПодробнее

How should molecular profiling be used to guide MDS therapy?Подробнее

Etiology and genetic profile of t-MDSПодробнее

7a-Are we ready to perform NGS in all MDS patients? - Part 1Подробнее

What is a genetic mutation, a biomarker, and cytogenetic analysis in MDS?Подробнее